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Severe combined immunodeficiency (SCID) and other severe non-SCID primary
immunodeficiencies (non-SCID PID) can be treated by allogeneic hematopoietic stem cell
(HSC) transplantation, but when histocompatibility leukocyte antigen-matched donors
are lacking, this can be a high-risk procedure. Correcting the patient’s own HSCs
with gene therapy offers an attractive alternative. Gene therapies currently being used
in clinical settings insert a functional copy of the entire gene by means of a viral
vector. With this treatment, severe complications may result due to integration within
oncogenes. A promising alternative is the use of endonucleases such as ZFNs, TAL-
ENs, and CRISPR/Cas9 to introduce a double-stranded break in the DNA and thus
induce homology-directed repair. With these genome-editing tools a correct copy can
be inserted in a precisely targeted “safe harbor.” They can also be used to correct
pathogenic mutations in situ and to develop cellular or animal models needed to study
the pathogenic effects of specific genetic defects found in immunodeficient patients. This
review discusses the advantages and disadvantages of these endonucleases in gene
correction and modeling with an emphasis on CRISPR/Cas9, which offers the most
promise due to its efficacy and versatility.
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Introduction
Primary immunodeficiencies (PIDs) comprise a heterogeneous group of rare, chronic diseases
in which part of the immune system is missing or functions improperly. PIDs are caused by a
myriad of different genetic defects and their clinical manifestations may vary significantly. On the
clinical spectrum of PID, severe combined immunodeficiency (SCID) is the most severe form of
immunodeficiency. SCID is caused by many different genetic mutations that result in a develop-
mental block in the production of T cells with an additional primary or secondary defect in B cells.
NK cells may be lacking as well. SCID is characterized by increased susceptibility to life-threatening
infections, particularly early in life. Newborn screening for SCID has been implemented in many
states in USA, facilitating early detection and improving treatment outcomes (1–3). In addition
to newborn screening, the advances in gene identification techniques, such as exome and genome
sequencing, have greatly enhanced diagnostic capabilities in the field of PID. Over 230 PID-causing
genes have been described and novel gene defects continue to be discovered (4). In parallel,
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the field of genome editing has progressed rapidly in the past few
years, and many new tools are now available. These greatly ease
the generation of in vitro models and animal models needed to
study Mendelian disorders such as PID. Genome-editing tech-
niques hold great promise for treatment by direct gene correc-
tion as well. This review will address these novel genome-editing
methodologies and how these tools can be applied to model and
correct PID.
Hematopoietic Stem Cell Transplantation
The current treatment of choice for SCID and other severe
forms of PID is allogeneic hematopoietic stem cell transplantation
(HSCT), which replaces defective hematopoietic lineages with
functional cells. If a histocompatibility leukocyte antigen (HLA)-
matched donor is available, conditioning chemotherapy is usually
not indicated, because the patient has no T cells to cause rejection
(5). However, HLA-matched donorsmay not be available. In those
cases, depending on donor source and SCID genotype/phenotype,
conditioning chemotherapymay be needed to facilitate robust and
sustained engraftment of donor cells and improve immune recon-
stitution (6). Although results of HSCT have greatly improved
over the years, when HLA-matched donors are lacking or when
the recipients suffer from ongoing active infections or other seri-
ous complications, clinical outcomes are still suboptimal (5–12).
This is due to risks of conditioning chemotherapy, graft rejection,
graft-versus-host disease (GvHD), and delayed immune reconsti-
tution. For these patients, gene therapy, in which gene-mutated
autologous hematopoietic stem cells (HSCs) are complemented
with a correct version of the gene, may offer an attractive alter-
native.
Gene Therapy Using Viral Vectors
In order to complement autologous HSCs, CD34+ HSCs are
harvested from the patient and then transduced with a viral vec-
tor containing a correct copy of the gene along with regulatory
elements that control gene expression, such as promoters and
enhancers. The viral vector allows integration of the therapeutic
transgene into the HSC genome. HSCs transduced with the vector
are then infused back into the patient. As in allogeneic HSTC, the
number of successfully transduced HSCs required to obtain opti-
mal reconstitution depends on the selective advantage of the cor-
rected HSCs over the patient HSCs without the correct gene (13).
In the first trials of gene therapy for PIDs, retroviral vectors were
used in which expression of the normal transgene was driven by
the retrovirus long terminal repeat (LTR).With this approach, suc-
cessful and durable T cell reconstitution was achieved in patients
with X-linked SCID [X-SCID (14, 15)], adenosine deaminase
(ADA) deficiency (16–20), andWiskott–Aldrich syndrome [WAS
(21, 22)]. Unfortunately, several patients developed leukemia.
These serious adverse events were caused by preferential integra-
tion of retroviral vectors in proximity of transcription initiation
sites of genes (including oncogenes) and by the strong enhancer
activity of the viral LTR, leading to increased and deregulated
expression of the targeted oncogenes (23–26).
To counter these adverse effects, much effort has gone in the
development of safer viral vectors. A gene therapy trial to correct
X-SCID using a self-inactivating retroviral (SIN-RV) vector, in
which the U3 enhancer was deleted from the LTR and expression
was driven by the weaker eukaryotic human elongation factor 1α
(EF1α) short promoter, is currently underway in Europe and in
theUSA. Preliminary results from this trial show a similar kinetics
of T cell recovery compared to that of the previous trial, but with
significantly less integration within proto-oncogenes. Long-term
safety effects remain to be studied (27). In addition to the safer
SIN-RV vectors, lentiviral vectors are promising. In vitro (28, 29)
and in vivo studies (30–32) have demonstrated that lentiviral
vectors integrate randomly in actively transcribed genes, without
any preference for the transcription initiation sites and regulatory
elements; thus, they are potentially safer (33). Therefore, several
trials using SIN lentiviral (SIN-LV) vectors have been initiated
(34), including a treatment trial of WAS that shows promising
results (35).
Genome Editing Using Endonucleases
While SIN-RV and SIN-LV vectors demonstrate a safer integra-
tion site profile, greater control over vector site integration is
still desired. Engineered endonucleases that introduce double-
stranded breaks (DSB) at specific sequences in the genomic DNA
offer much more control over the integration site of viral vectors.
Cells repair a DSB either through the error-prone process of non-
homologous end-joining (NHEJ) or through homology-directed
repair (HDR) in which a highly homologous template, either
a sister chromatid or an exogenous double-stranded or single-
stranded DNA template, is copied accurately. HDR can be used
to either insert a gene into a specific “safe harbor” or to replace
a defective gene in situ (Figure 1). “Safe harbors” are regions in
genomic DNA that do not contain oncogenes and that can be
disrupted without adverse consequences. One such safe harbor
is the adeno-associated virus integration site 1 (AAVS1) locus.
In order to insert a functional copy of the PID-causing gene
into a specific locus, such as AAVS1, one can use an engineered
endonuclease to introduce a DSB at the site and a DNA repair
template containing the gene flanked by two homology arms that
match the AAVS1 sequence (36–39).
Alternatively, instead of adding a normal copy of the gene in
the “safe harbor,” one can correct the defective PID gene in situ.
In this case, the DSB is introduced close to the mutation, and
then, a repair template, containing the correct sequence flanked
by two homology arms matching the sequences surrounding
the target site, is inserted. When correcting the actual mutation
itself, the endogenous promoter, enhancer, and other regulatory
elements are used, and thus, physiological gene expression is
preserved. This is beneficial when aiming to correct tightly reg-
ulated genes, such as Recombination-activation gene 1 (RAG1)
and Recombination-activation gene 2 (RAG2), the genes required
for VDJ recombination during T cell and B cell development
(40). In addition, in situ correction is ideal for dominant-negative
mutations; in these cases, simple addition of the normal gene
would be inadequate to rescue the phenotype, and a specific
correction of the mutation is required. The endonucleases can be
designed to only target the mutant sequence and spare the wild-
type sequence. For the majority of PIDs, the disease phenotype is
caused by recessive mutations. In these cases, correcting one allele
is sufficient to rescue the phenotype.
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FIGURE 1 | A double-stranded break (DSB) in the DNA can be
repaired through the process of homologous recombination (HDR)
or through the error-prone process of non-homologous
end-joining (NHEJ). In HDR, a template is used to correct the DSB.
HDR can be used to precisely introduce a gene or part of a gene or even
a point mutation, whereas NHEJ can result in insertions and/or deletions
(indels) around the DSB. An indel can lead to a frameshift and an early
stop codon.
When using engineered endonucleases, several aspects need
to be considered. First, the efficiency of introducing DSBs at the
target site, the on-target efficiency, is important. When testing
the endonuclease, on-target efficiency can be inferred from the
proportion of alleles in a batch of cells showing deletions or inser-
tions (indels) at the target site, because some of the introduced
DSBs were repaired by the error-prone process of NHEJ. These
indels can be easily captured using next-generation sequencing
or alternatively, by studying the heteroduplex DNA hybridization
of PCR products from the target site (e.g., with the Surveyor®
assay). Second, a common concern with the use of endonucleases
is off-target mutagenesis. This is the inadvertent introduction
of mutations caused by DSBs at genomic sites other than the
target site. Currently, several sequencing techniques are available
to check for off-target mutagenesis. Some will be addressed in the
next section when discussing different endonucleases.
A third aspect that needs to be considered when using engi-
neered endonucleases is how to deliver the endonuclease and
the DNA template to the cell. For ex vivo therapeutic applica-
tions, such as gene targeting in HSCs harvested from a patient,
nucleofection is a non-viral method to introduce polynucleotides
into the cells (41). Its disadvantages include toxicity to the cells
and low efficiency. Alternatively, viral vectors that do not inte-
grate in the genome, such as integrase-deficient lentiviral vectors,
adenoviral vectors, and vectors based on adeno-associated viruses
can be used. These viruses enter the cell and express the endonu-
clease, without inserting it into the genome. These have been
proven effective tools to deliver both the repair constructs and the
endonucleases (42–45). In vivo therapeutic applications present a
greater challenge in that the delivery method must efficiently and
specifically target the desired cells and spare the other cells within
the whole body.
ZFNs, TALENs, and CRISPR/Cas9
Although a number of different genome-editing technologies are
now in use, we describe three types of engineered endonucleases
that have found broad use in the biomedical community, with a
particular focus on the most recently developed nuclease system,
CRISPR/Cas9, which has attracted widespread attention for its
efficacy and versatility (Figure 2).
Zinc Finger Nucleases
Zinc finger nucleases (ZFNs) consist of a pair of endonuclease
domains of the bacterial FokI restriction enzyme flanked by two
site-specific DNA-binding domains (Figure 2A). Upon binding
of these domains, the FokI domains dimerize and introduce a
DSB (46). Even though academic consortia have developed open-
source libraries for ZFN construction (42, 47), engineering of site-
specific ZFNs remains difficult for non-specialists. Depending
on the ZFN architecture used, only limited sites in a genomic
region can be targeted, which might be problematic if a specific
mutation needs to be corrected (43–45, 48). One study showed
off-target mutagenesis with ZFNs in one out of ten sites with a
sequence similar to the target site (37). Two other studies also
found that DSBs were introduced in off-target sites using ZFNs
in a human tumor cell line (49, 50). One of the ZFNs tested
was designed to correct mutations causing X-SCID, i.e., muta-
tions in the gene encoding the Interleukin 2 receptor gamma
(IL2RG) (49, 51). Variants of the endonucleases have been devel-
oped to reduce off-target mutagenesis. These consist of a mix
of two distinct ZFNs with different FokI domains that are obli-
gate heterodimers, such that a ZFN pair introduces a DSB only
when the two distinct ZFNs are able to bind adjacent DNA
regions (52–54).
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FIGURE 2 | Schematic representation of ZFNs, TALENs, and
CRISPR/Cas9. (A) Two ZFN dimers bind DNA and position their FokI nuclease
domains such that they dimerize and generate a double-stranded break (DSB)
between the binding sites. (B) TALENs, like ZFNs, bind DNA and generate a
DSB upon dimerization of their FokI domains. (C) In the most commonly used
CRISPR/Cas9 system, Cas9 forms a complex with a gRNA that recognizes and
hybridizes a 20-bp protospacer in the genome. Cas9 binds the adjacent PAM
sequence and introduces a DSB 3bp upstream of the PAM sequence. (D) Cas9
nickases (Cas9n) are mutant variants that bind to flanking DNA sequences and
generate single-strand nicks instead of DSBs. Two nicks are the equivalent of a
DSB. (E) Another variant consists of catalytically inactive Cas9 (fCas9) fused to
a FokI nuclease domain. When two FokI nucleases dimerize because the Cas9
proteins bind to flanking DNA sequences, a DSB is introduced between the
binding sites.
Transcription Activator-Like Effector Nucleases
Transcription activator-like (TAL) domains are tandem arrays
with 10–30 repeats, each 33–35 amino acids long that bind and
recognize extended DNA sequences (55). One domain of the TAL
repeats is fused to a FokI endonuclease domain, creating a TAL
effector nuclease (TALEN), similar to the ZFN. Upon binding of
the two TALENs to flanking DNA sequences, the FokI domains
dimerize and introduce a DSB at the target site (Figure 2B).
TALENs are easier to design and have fewer constraints on site
selection than ZFNs. A disadvantage of using TALENs is their
size. The DNA sequence encoding each TALEN is more than
3 kb in size, compared to only 1 kb for each ZFN. The larger size
makes it harder to deliver TALEN-expressing plasmids into cells.
Moreover, the highly repetitive nature of TALEN sequences due
to their tandem arrays makes them more challenging to package
into viral vectors for delivery (56).With respect to off-targetmuta-
genesis, two studies showed this phenomenon was minimal with
TALENs (57, 58). Unfortunately, not many studies have compared
TALENs and ZFNs directly. However, one study suggested that
when targeting the CCR5 gene, less off-target mutagenesis was
seen with TALENs than with ZFNs (59).
CRISPR/Cas9
The latest in a series of new genome-editing tools is the
clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR associated 9 (Cas9) system. Cas9 is a protein
used by bacteria to destroy foreign DNA. The foreign DNA is
cleaved and incorporated as small sequences – called protospacer
sequences – into the bacterial genome, and these sequences are
then transcribed as short CRISPR RNAs (crRNAs). These crRNAs
are then used to target and destroy any foreign DNA sequences
that enter the cell and match those sequences. The bacterial Cas9
nuclease and a crRNA form a ternary complex with a second
RNA component, the trans-activating crRNA (tracrRNA), which
has a fixed sequence. This complex can engage double-stranded
DNA, with the crRNA hybridizing the protospacer sequence and
Cas9 binding a specific protospacer-adjacent motif (PAM). Once
the complex is engaged, Cas9 introduces a DSB 3 bp upstream
of the PAM (60). After the characterization of the CRISPR/Cas9
system in bacteria, investigators found that it could be used
to introduce DSBs efficiently in mammalian DNA. The RNA
components of the CRISPR/Cas9 system can be separate crRNA
and tracrRNA molecules, or the two RNA molecules can be
combined into a single guide RNA [gRNA (61–64)]. The Cas9
protein from the species Streptococcus pyogenes is the most
commonly used at present and uses a PAM with the sequence
NGG. When Cas9 is used with a single gRNA (as is now usually
the case), CRISPR/Cas9 represents a simple two-component
system (Figure 2C).
The advantages of CRISPR/Cas9 are the high efficiency of
introducing DSBs into the genomes of mammalian cells and the
ease of engineering. TheCas9 nuclease is always the same; to target
a different region of the genome, only the protospacer region
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(20 nucleotides) of the gRNA needs to be altered. While theo-
retically the PAM requirement could be a limitation, on average
the NGG PAM sequence needed by S. pyogenes Cas9 can be
found every 8 bp in the genome, making it very likely to find a
CRISPR/Cas9 target site near the mutation that needs to be cor-
rected (63). In contrast, the PAM sequence used by Streptococcus
thermophilus Cas9, NNAGAAW, occurs on average every 64 bp;
the Neisseria meningitidis Cas9 protein requires a NNNNGATT
PAM, which occurs on average every 128 bp (63, 65, 66).
As with other engineered nucleases, the main concern regard-
ing the use of CRISPR/Cas9 is off-target mutagenesis. Such muta-
genesis appears to be highly gRNA dependent and most often
occurs at sites with sequence similarity to the protospacer, with
up to severalmismatches tolerated;moremismatches are tolerated
as the distance from the PAM increases (61, 62, 67–70). The
number of potential off-target binding sites of Cas9 can vary
widely, depending on the gRNA used (71, 72).
Moreover, some studies suggest that even when the
CRISPR/Cas9 is able to bind to an off-target site, the mismatches
prevent actual DNA cleavage (45, 48). A novel method to
systematically assess off-target mutagenesis, the so-called
genome-wide, unbiased identification of DSBs, enabled by
sequencing (GUIDE-seq), was recently reported (73). This
method is based on the detection of small synthetic double-
stranded DNA oligodeoxynucleotides that are incorporated in
the genomic DNA at the site of the DSBs through NHEJ.
To reduce off-target mutagenesis, many different variants of
the CRISPR/Cas9 system with higher target specificity are being
developed. In one strategy, the length of the gRNA protospacer
is reduced by up to three nucleotides, which appears to make the
gRNA less tolerant of mismatches and less likely to bind to off-
target sites, thereby reducing the rate of off-target mutagenesis
(74). A different approach uses Cas9 “nickases,” which aremutated
variants of Cas9 that each introduce a single-stranded break
(called a nick) instead of a DSB (Figure 2D). When two distinct
gRNAs matching to two distinct sequences flanking the target
site are used, Cas9 will produce two separate nicks that together
are the equivalent of a DSB and can thus induce repair by NHEJ
or HDR. Off-target mutagenesis is substantially reduced with the
double-nickase strategy because the two nicks occur in proximity
only when Cas9 binds to two adjacent sequences that resemble
the protospacers, which is very unlikely to occur elsewhere in the
genome (75–77). Finally, investigators have combined the most
desirable properties ofCRISPR/Cas9 andZFNs/TALENs by fusing
a catalytically dead Cas9 to a FokI domain. Two Cas9-FokI fusion
proteins are guided to flanking sequences around a target site by a
pair of gRNAs. Upon DNA binding of the Cas9 domains, the FokI
domains dimerize and generate a DSB (Figure 2E). As with the
double-nickase strategy, binding of Cas9 to two separate nearby
sequences is required for the generation of a DSB, and accordingly
the off-target mutagenesis rate is greatly reduced (78, 79).
Genome Editing Results in Human
Stem Cells
A number of studies have demonstrated the feasibility of
genome editing in human stem cells with ZFNs, TALENs, and
CRISPR/Cas9 (36, 37, 51, 62, 77, 80–84). In one such study,
intestinal stem cells of cystic fibrosis patients with homozy-
gous delta508 mutations in the CFTR gene were corrected using
CRISPR/Cas9. Corrected and uncorrected stem cells were differ-
entiated into organoids and compared. The corrected organoids
showed swelling in response to forskolin treatment, as expected
in the presence of a functional CFTR protein, whereas the mutant
organoids failed to swell (85). Another group transfected human
HSCs with ZFNs that disrupted CCR5, the chemokine recep-
tor used by human immunodeficiency virus (HIV) to infect
cells. The targeted cells were transplanted into immunodefi-
cient NOD/SCID/IL2rγ-null (NSG) mice, which then exhibited
human hematopoiesis. Moreover, when the transplanted mice
were infected with HIV, there was a selective survival advan-
tage for the CCR5 knockout cells, protection of the human-
derived T cell populations, and a reduction in HIV viral
load (41).
In SCID and most types of PID, multiple cell types of the
immune system are defective. In order to restore the immune
function one needs to target the patient’s own HSCs (84). The
most common form of SCID, X-SCID, is caused by mutations in
the gene encoding interleukin 2 receptor gamma (IL2RG). Several
groups have successfully used ZFNs to target and induce HDR
in the IL2RG locus in various human cell types, including HSCs
and embryonic stem cells [ESCs (51, 84, 86)]. One of these studies
corrected an IL2RG mutational hotspot in HSCs using ZFNs and
showed multilineage hematopoietic differentiation upon trans-
plantation of gene-corrected cells into NSG mice (84). Another
study successfully used specific TALENs to target and induceHDR
in the IL2RG locus of Jurkat cells (87).
Challenges when targeting HSCs are the low efficiency of HDR
and the risk of losing multilineage potential when manipulating
and expanding gene-corrected cells in vitro. Several cell types,
such as T cells, HSCs, and fibroblasts, can be reprogramed into
induced pluripotent stem cells (iPSCs) by transducing these cells
with a SIN-lentiviral vector expressing three pluripotency genes,
OCT4, SOX2, and KLF4 (88–90). Studies have shown the feasi-
bility of iPSC gene targeting to correct hematopoietic diseases,
such as sickle cell disease in vitro using ZFNs (82, 91) or TAL-
ENs (92). Many different iPSCs from a number of patients with
distinct immunodeficiencies have now been generated (38, 39,
93, 94). These patient iPSCs can be corrected, or alternatively,
an original patient somatic cell can be corrected before being
reprogramed into iPSCs. ZFNs have been used to correct chronic
granulomatous disease (CGD) by introducing up to five different
functional genes into the AAVS1 safe harbor in iPSCs generated
from peripheral HSCs. Using in vitro myeloid differentiation,
normal granulocyteswere generated from the corrected iPSCs (38,
39). Successful differentiation of human iPSCs into T cells in vitro
has been recently reported (95–97), making it possible to test the
ability of genome editing to restore T cell differentiation capacity
of iPSCs from patients with SCID. However, in vivo use of gene-
edited iPSCs for correction of human PIDs is not yet ready for
the clinic because of safety concerns related to the tumorigenic
potential of iPSCs andbecause of difficulty in generating definitive
HSCs from human iPSCs. Nonetheless, these recent achievements
with in vitro targeted differentiation of human iPSCs have great
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value in that they enable preclinical efficacy and safety studies
of genome-editing approaches that may eventually be applied to
human HSCs.
Modeling PIDs Using Genome Editing
In vitro Models
Even though gene targeting using engineered endonucleases is
not ready to be applied in a clinical setting, it already offers a
valuable tool to model diseases at the cellular level. CRISPR/Cas9
has been shown to be particularly efficient in the generation of
knockout cell lines; as described above, after a DSB has been
introduced into the genomic region matching the protospacer
sequence of the gRNA, the cell uses either HDR or NHEJ to
repair the defect. NHEJ can result in indels, which in turn can
cause frameshifts and the occurrence of premature stop codons.
A knockout cell generated in this way can be clonally expanded
into a cell line that can be used for modeling studies. In addition,
a useful property of the CRISPR/Cas9 system is that multiple
genes can be knocked out simultaneously if several gRNAs are
used together (multiplexing). A particular advantage compared
to RNA interference is that CRISPR/Cas9 can be used to target
regions in the non-coding genome [e.g., promoter and enhancer
regions (98–101)].
The advent of next-generation sequencing has stimulated a
new wave of discovery of novel inborn errors of immunity (102).
The ability to correct patient-specific iPSCs, or conversely, to
introduce patient-specific mutations into a wild-type iPSC line
using endonucleases represents an invaluable tool to prove the
pathogenicity of newly discovered mutations and to gain insight
into disease mechanisms in different cell types, depending on
patients’ phenotypes. This approach alsomakes it possible to study
the contribution of genetic background to the phenotypes arising
from specific mutations by comparing patient-derived iPSCs with
wild-type iPSCs into which the same mutations are introduced
(Figure 3). In a recent study, iPSCs were generated from patients
with Parkinson disease caused by the G2019S mutation of the
LRRK2 gene and from healthy controls. When comparing the
whole-genome gene expression patterns, the investigators found
a high degree of heterogeneity among the different iPSCs lines.
However, when they used ZFNs to correct the mutation in three
of the patient-derived iPSC lines and compared these lines to
FIGURE 3 | In vitro modeling. (A) Induced pluripotent stem cells (iPSCs) are
reprogrammed from a patient(s) and from a healthy control(s). The iPSCs are
differentiated into a cell type of interest, and the phenotypes of the
patient-derived cells are compared to the phenotypes of the healthy control cells.
The cells that are compared do not have the exact same genetic background
(genetically and epigenetically unmatched). This can lead to confounding.
(B) Using genome editing with engineered nucleases like ZFNs, TALENs, and
CRISPR/Cas9, a pathogenetic mutation can be corrected in patient-derived cells
or introduced into healthy control cells, and isogenic cell lines (i.e., identical
genetic background) can be compared for relevant phenotypes.
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the original lines, and when they introduced the mutation into a
healthy control line and compared this line to the original line,
the lines were much more closely matched with respect to gene
expression (83). This shows the importance of comparing isogenic
lines, as confounding due to differences in genetic background is
minimized.
Animal Models
Traditionally, animal models have been generated using
homologous recombination: embryonic stem cells (ESCs)
are electroporated with a highly homologous DNA template
containing the sequence to be inserted but without using an
engineered endonuclease to introduce a DSB. This approach
results in a very low efficiency and requires the inclusion
of an antibiotic resistance gene in the inserted sequence for
the selection of cells in which HDR has occurred. ESCs with
the desired inserted sequence are then expanded, injected
in blastocysts, and subsequently implanted in pseudogestant
females. The resulting chimeric animals have to be further
bred until the introduced mutation is transmitted through the
germline. With the currently available genome-editing tools, this
process can be greatly streamlined. Via the introduction of a DSB
at the desired target site, a specific sequence can be efficiently
introduced into ESCs without the need for an antibiotic resistance
gene. Furthermore, to create a gene knockout, one can simply
rely on NHEJ to produce indels leading to frameshifts and early
stop codons.
In recent years, many animal models have been successfully
generated using ZFNs, TALENs, or CRISPR/Cas9. TALENs and
CRISPR/Cas9 have been used to generate knockout Caenorhab-
ditis elegans models by injecting the endonucleases into the
gonads (103–105). Similarly, more complicated animal models
can be generated by injecting the endonucleases in mRNA form
directly in zygotes (Figure 4). In the case of CRISPR/Cas9, this
means that both the Cas9 and gRNA in RNA form are injected.
Knock-in models can be generated by adding a DNA template
to the injection mix, usually in the form of a single-stranded
DNA oligonucleotide. Zebrafish models have been generated by
injecting ZFNs or TALENs or CRISPR/Cas9 directly into the
zygote (106–109). This has been done in murine zygotes with
ZFNs (110–112), TALENs (113, 114), and extremely efficiently
with CRISPR/Cas9 (115–117). New mouse models can be gen-
erated in just a few weeks, instead of taking 1–2 years as in
the conventional strategy. With CRISPR/Cas9, the specific gRNA
needed for the injections can be generated in a simple one-
day procedure (118). NSG mice have been efficiently generated
in this way (119). In other studies, the IgM locus has been
successfully knocked out in rats via the injection of ZFNs and
TALENs directly into the zygotes (120, 121). Similarly, a rat
model of X-SCID has been generated using ZFNs (122). The
multiplexing capacity of CRISPR/Cas9 has allowed for multi-
ple genes being knocked out simultaneously (123). Endonucle-
ases have been used to generate knockout models in animals
not previously amenable to efficient genetic modification: rab-
bits with IL2RG, RAG1, or RAG2 knockout (124–127); hamsters
with STAT2 knockout (128); mutant pigs (129–131); and most
FIGURE 4 | Schematic representation of zygote injection with
CRISPR/Cas9. (A) Injection of gRNA and Cas9 will lead to indels that can
lead to a frameshift and an early stop codon thereby creating Knockout (KO)
mice. (B) Addition of a highly homologous DNA template containing a specific
mutation will result in Knock-in (KI) mice, through the process of
homology-directed repair (HDR). Reagents are injected in the cytoplasm of
the zygote. Alternatively, these can be injected in the pronucleus of the
zygote, but cytoplasmic microinjection is simpler and less toxic.
impressively, monkeys with RAG1 knockout (132). These kinds
of animal models will enable disease studies of unprecedented
sophistication.
Conclusion
During the last few years, the field of genome editing has shown
tremendous progress. Currently, several endonucleases are avail-
able. We have described their advantages and disadvantages and
how they can be used to model and correct PIDs. Efficiency and
ease will continue to improve with further refinement of these
tools, while endonuclease variants with increased specificity are
being actively developed. To use genome editing in a clinical
setting for the treatment of PID will require a further reduction
in off-target mutagenesis and an improved yield of gene-corrected
HSCs so that a sufficient number of cells for autologous transplan-
tation and engraftment can be obtained. Despite of these issues,
we expect the impact of genome editing on modern medicine to
be revolutionary.
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